Search Result

Results for "

lysosomal function

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Akt (1) Amyloid-β (2) Apoptosis (10) Atg8/LC3 (1) Autophagy (5) BCL6 (4) Caspase (4) Cathepsin (1) DNA/RNA Synthesis (1) Dopamine Receptor (2) Drug Metabolite (1) Endogenous Metabolite (4) ERK (2) Ferroptosis (1) Fungal (1) Glutathione Peroxidase (1) Glycosidase (2) Herbicide (1) IFNAR (2) Interleukin Related (5) Lipase (2) Mitochondrial Metabolism (1) mTOR (3) NADPH Oxidase (1) Necroptosis (1) NF-κB (2) PDGFR (2) Phosphatase (1) Potassium Channel (1) Pyruvate Kinase (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4) RIP kinase (1) SARS-CoV (2) STAT (4) TRP Channel (2) Wnt (1) YAP (1) β-catenin (1) β-glucuronidase (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (5) Metabolic Disease (9) Neurological Disease (11)

By Targets:

5-HT Receptor (1)

Adrenergic Receptor (1)

Akt (1)

Amyloid-β (2)

Apoptosis (10)

Atg8/LC3 (1)

Autophagy (5)

BCL6 (4)

Caspase (4)

Cathepsin (1)

DNA/RNA Synthesis (1)

Dopamine Receptor (2)

Drug Metabolite (1)

Endogenous Metabolite (4)

ERK (2)

Ferroptosis (1)

Fungal (1)

Glutathione Peroxidase (1)

Glycosidase (2)

Herbicide (1)

IFNAR (2)

Interleukin Related (5)

Lipase (2)

Mitochondrial Metabolism (1)

mTOR (3)

NADPH Oxidase (1)

Necroptosis (1)

NF-κB (2)

PDGFR (2)

Phosphatase (1)

Potassium Channel (1)

Pyruvate Kinase (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

RIP kinase (1)

SARS-CoV (2)

STAT (4)

TRP Channel (2)

Wnt (1)

YAP (1)

β-catenin (1)

β-glucuronidase (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (5)

Metabolic Disease (9)

Neurological Disease (11)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2334

Glycochenodeoxycholic acid 5 Publications Verification Chenodeoxycholylglycine	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N2334A

Glycochenodeoxycholic acid sodium salt 5 Publications Verification Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate	Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-W011063

Gly-Phe-β-naphthylamide	Cathepsin	Metabolic Disease
Gly-Phe-β-naphthylamide is a substrate of Cathepsin C (HY-P2922) and belongs to the lysosomal agonist. Gly-Phe-β-naphthylamide can freely pass through the cell membrane and organelle membrane. Gly-Phe-β-naphthylamide will be specifically hydrolyzed by Cathepsin C, ultimately leading to a permeability lysis when it enters the acidic compartment. Gly-Phe-β-naphthylamide can be used to study lysosomal hydrolysis, lysosomal membrane permeability, and the function of cathepsin C .

HY-128144

Lalistat 2 3 Publications Verification	Lipase	Metabolic Disease
Lalistat 2 is an inhibitor of many lipases especially Lysosomal acid lipase (LAL, IC₅₀ = 152 nM), which is a key enzyme that degrades neutral lipids at an acidic pH in lysosomes. Lalistat 2 is commonly used to investigate the cell-specific functions of LAL and LAL deficiency in vitro, as well as specifically measure LAL activity in human blood samples or cells .

HY-134819A

(1R,2R)-ML-SI3 3 Publications Verification (-)-trans-ML-SI3	TRP Channel	Neurological Disease
(1R,2R)-ML-SI3 is an isomer of ML-SI3 and a potent inhibitor of three isoforms of TRPML. (1R,2R)-ML-SI3 inhibits TRPMLs with IC₅₀s of 1.6 μM (TRPML1), 2.3 μM (TRPML2), and 12.5 μM (TRPML3), respectively .

HY-N1163

Tetrahydroalstonine (-)-Tetrahydroalstonine	Adrenergic Receptor Atg8/LC3 Akt mTOR	Neurological Disease Endocrinology
Tetrahydroalstonine ((-)-Tetrahydroalstonine) is an indole alkaloid and a selective α₂-adrenergic receptor antagonist. Tetrahydroalstonine exhibits certain neuroprotective effects. Tetrahydroalstonine can regulate autophagy-lysosomal function by activating the Akt/mTOR pathway, significantly reducing OGD/R-induced primary cortical neuronal injury .

HY-137978A

Ezurpimtrostat hydrochloride 3 Publications Verification GNS561 hydrochloride	SARS-CoV IFNAR Autophagy Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-161949

AP-6 1 Publications Verification	Potassium Channel	Neurological Disease
AP-6 is a selective inhibitor of TMEM175 with activity in modulating lysosomal function. Acute inhibition of TMEM175 by AP-6 increases lysosomal macromolecular catabolism, thereby accelerating macrophage and other digestive processes. AP-6 may be used in Parkinson's disease research .

HY-P5381

gp91 ds-tat 1 Publications Verification	NADPH Oxidase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase TRP Channel	Cardiovascular Disease Neurological Disease Inflammation/Immunology
gp91 ds-tat, a biological active peptide, is a NADPH oxidase 2 (Nox2) inhibitor. gp91 ds-tat blocks NADPH oxidase-dependent superoxide production. gp91 ds-tat ameliorates high glucose-induced increase in total ROS, LPOs and iron levels. gp91 ds-tat inhibits homocysteine (Hcy)-induced activation of NLRP3 inflammasomes and restores Hcy-inhibited lysosomal TRPML1 channel activity. gp91 ds-tat improves cerebrovascular and cognitive function in APP/PS1 mice. gp91 ds-tat can be used for the study of Alzheimer’s disease (AD), glomerular inflammation and cardiovascular disease .

HY-148755

ERX-41	Lipase	Cancer
ERX-41 is an orally active and stereospecific small molecule targeting to lysosomal acid lipase A (LIPA). ERX-41 induces endoplasmic reticulum (ER) stress resulting in cell death, indicating a function independent of LIPA but dependent on its ER localization. ERX-41 involves in a targeted strategy for solid tumors .

HY-137978

Ezurpimtrostat 3 Publications Verification GNS561	SARS-CoV IFNAR Autophagy Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-170035

GlcCer (d18:1/18:0) C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine	Fungal Wnt β-catenin	Infection Neurological Disease Cancer
GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipids that activates the Wnt/β-catenin pathway by targeting LRP6. GlcCer (d18:1/18:0) drives EMT, migration, invasion and GBA1-mediated liver cancer metastasis. GlcCer (d18:1/18:0) accumulates to impair lysosomal function and induce toxic α-synuclein aggregation. GlcCer (d18:1/18:0) supports growth, sporulation, germination and virulence in Penicillium digitatum. GlcCer (d18:1/18:0) is reduced in demyelinated mouse corpus callosum. GlcCer (d18:1/18:0) can be used for the research of liver cancer, synucleinopathies, fungal, Parkinson’s disease and Gaucher disease .

HY-137572

(R)-DOI hydrochloride	5-HT Receptor	Neurological Disease Inflammation/Immunology
(R)-DOI hydrochloride is a selective 5HT2A receptor agonist. (R)-DOI hydrochloride has anti-inflammatory, anti-oxidative stress, and lysosomal function-improving effects. (R)-DOI hydrochloride can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease .

HY-N2334R

Glycochenodeoxycholic acid (Standard) Chenodeoxycholylglycine (Standard)	Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid (Standard) is the analytical standard of Glycochenodeoxycholic acid. This product is intended for research and analytical applications. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].

HY-N2334AR

Glycochenodeoxycholic acid sodium salt (Standard) Chenodeoxycholylglycine sodium salt (Standard); Sodium glycochenodeoxycholate (Standard)	Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase	Metabolic Disease Cancer
Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-N7526R

Naphthazarin (Standard) DHNQ (Standard); 5,8-Dihydroxy-1,4-naphthoquinone (Standard)	Reference Standards Apoptosis	Neurological Disease Cancer
Naphthazarin (DHNQ) is a naturally occurring compound. Naphthazarin is effective by various cellular mechanisms including oxidative stress, activation of mitochondrial apoptosis-inducing factor (AIF), depolymerization of microtubules, interference with lysosomal function and p53-dependent p21 activation. Naphthazarin triggers apoptosis and has anti-tumor effects .

HY-179214

DEL-C1	Glycosidase Amyloid-β NF-κB Interleukin Related	Neurological Disease
DEL-C1 is a CHI3L1 inhibitor. DEL-C1 can restore the ability to clear Amyloid-β and repair lysosomal function of astrocytes. DEL-C1 can inhibit NF-κB signaling and IL-6 secretion. DEL-C1 can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease .

HY-138813R

N-Desethyl Sunitinib hydrochloride (Standard) SU-12662 hydrochloride (Standard)	Reference Standards Drug Metabolite	Cancer
Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .

HY-203817

IITZ-02	Autophagy Apoptosis Mitochondrial Metabolism	Cancer
IITZ-02 is a lysosomotropic Autophagy inhibitor. IITZ-02 enhances autophagosome accumulation but inhibits autophagosomal degradation by impairing lysosomal function, finally inducing the inhibition of autophagy. IITZ-02 abolishes mitochondrial membrane potential and induces apoptosis through the mitochondria-mediated pathway. IITZ-02 has a potent antitumor activity in MDA-MB-231 xenograft mouse models. IITZ-02 can be used for cancers research .

HY-173150

Hapalindole Q	YAP	Cancer
Hapalindole Q (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. Hapalindole Q binds to the Hippo pathway transcription factor YAP1 with a K_d of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. Hapalindole Q holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) .

HY-101349

L 741742	Dopamine Receptor Apoptosis Autophagy PDGFR ERK mTOR	Neurological Disease Cancer
L 741742 is a highly selective and brain-penetrant D4 dopamine receptor antagonist, with K_i values of 3.5 nM, 770 nM and >1700 nM for human D4, D3 and D2 receptors, respectively. L 741742 suppresses PDGFRβ, ERK1/2, and mTOR signaling pathways, and impairs autophagic flux while disrupting lysosomal function.L 741742 induces G0/G1 cell-cycle arrest and apoptosis, promotes neuronal differentiation of normal human neural stem cells, selectively inhibits growth and clonogenic potential of glioblastoma neural stem cells and primary glioblastoma tumor cells, exerts synergistic effects with Temozolomide (TMZ) (HY-17364) against glioblastoma neural stem cells in vitro, and inhibits glioblastoma neural stem cell xenograft growth in immunocompromised mice. L 741742 can be used for the research of schizophrenia and glioblastoma .

HY-101349A

L 741742 hydrochloride	Dopamine Receptor Apoptosis Autophagy PDGFR ERK mTOR	Neurological Disease Cancer
L 741742 hydrochloride is a highly selective and brain-penetrant D4 dopamine receptor antagonist, with K_i values of 3.5 nM, 770 nM and >1700 nM for human D4, D3 and D2 receptors, respectively. L 741742 hydrochloride suppresses PDGFRβ, ERK1/2, and mTOR signaling pathways, and impairs autophagic flux while disrupting lysosomal function.L 741742 hydrochloride induces G0/G1 cell-cycle arrest and apoptosis, promotes neuronal differentiation of normal human neural stem cells, selectively inhibits growth and clonogenic potential of glioblastoma neural stem cells and primary glioblastoma tumor cells, exerts synergistic effects with Temozolomide (TMZ) (HY-17364) against glioblastoma neural stem cells in vitro, and inhibits glioblastoma neural stem cell xenograft growth in immunocompromised mice. L 741742 hydrochloride can be used for the research of schizophrenia and glioblastoma .

HY-180899

CHI3L1-IN-5	Glycosidase Amyloid-β NF-κB	Neurological Disease
CHI3L1-IN-5 (Compound Z17) is a highly selective CHI3L1 inhibitor with a K_D value of 6 μM. CHI3L1-IN-5 restores the clearance ability of astrocytes by rejuvenating lysosomal function and Aβ uptake. CHI3L1-IN-5 alleviates neuroinflammation by inhibiting the NF-κB pathway. CHI3L1-IN-5 can be used for research on Alzheimer's disease .

HY-185306

Morfamquat dichloride PP 745	Herbicide Phosphatase β-glucuronidase	Metabolic Disease
Morfamquat dichloride (PP 745) is a bipyridine herbicide. Acute poisoning by Morfamquat dichloride strongly stimulates the reticuloendothelial system, causes lysosomal membrane damage and enzyme leakage, and interferes with the function of hepatocyte Golgi apparatus and related glucose metabolic pathways. Morfamquat dichloride significantly increases the activities of acid phosphatase and β-glucuronidase, exerting toxic effects on mice, while pre-administration of vitamin E alleviates such toxicity .

HY-183781

RIPK1-IN-41	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-41 is an orally active RIPK1 inhibitor with an IC₅₀ of 92 nM and a K_D of 106.8 nM. RIPK1-IN-41 reduces the phosphorylation level of RIPK1, inhibits necrosome formation, blocks the activation of RIPK3 and MLKL, maintains mitochondrial and lysosomal functions, preserves cell membrane integrity, and suppresses necroptosis. RIPK1-IN-41 alleviates hypothermia and multi-organ damage in a mouse model of systemic inflammatory response syndrome induced by mTNF-α. RIPK1-IN-41 is applicable to research related to systemic inflammatory response syndrome .

HY-182037

Multi-target kinase-IN-9	DNA/RNA Synthesis Pyruvate Kinase	Cancer
Multi-target kinase-IN-9 is a multi-target enzyme inhibitor with antiproliferative and antiangiogenic activities, and exhibits remarkable selectivity against hepatocellular carcinoma cells. By broadly binding to the active sites or ATP-binding regions of multiple key enzymes including DNA polymerase β, Pyruvate Kinase M2 (PKM2), Multi-target kinase-IN-9 comprehensively disrupts DNA repair and replication, glycolysis, chromatin dynamics and transcriptional programs, and blocks the self-renewal of cancer stem cells. Multi-target kinase-IN-9 induces genomic instability, lysosomal dysfunction and autophagic flux impairment, thereby triggering tumor cell death, effectively inhibiting tumor proliferation, invasion, metastasis and angiogenesis, and significantly reducing tumor volume in xenograft models. Multi-target kinase-IN-9 is applicable to hepatocellular carcinoma-related research .

Cat. No.	Product Name	Target	Research Area